References
-
Aleyasin A, Hanafi S, Saffarieh E, et al (2012). Efficacy of generic granisetron vs
$Kytril^{(R)}$ for PONV in major gynecological operations: a randomized, double-blind clinical trial. Iranian J Pharm Res, 11, 1059-64. - Almazron S and Alnaim L (2012). Evaluation of adherence to chemotherapy-induced nausea and vomiting guidelines. An observational study. J Cancer Therapy, 3, 613-20. https://doi.org/10.4236/jct.2012.35078
- Annemans L, Strens D, Lox E, et al (2008). Cost-effectiveness analysis of aprepitant in the prevention of chemotherapyinduced nausea and vomiting in Belgium. Support Care Cancer, 16, 905-15. https://doi.org/10.1007/s00520-007-0349-1
- Ballatori E, Roila F, Berto P, et al (1994). Cost and costeffectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy. Pharmacoeconomics, 5, 227-37. https://doi.org/10.2165/00019053-199405030-00006
- Burmeister H, Achi S, Studer C, et al (2012). Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Supp Care Cancer, 20, 141-7. https://doi.org/10.1007/s00520-010-1079-3
- Chan HK, Phua G, Kassim MS, et al (2013). Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low-emetogenic chemotherapy? Asian Pac J Cancer Prev, 14, 469-73. https://doi.org/10.7314/APJCP.2013.14.1.469
- Colayco DC and Hay J (2010). Cost-effectiveness of serotonintype 3 receptor antagonists for chemotherapy-induced emesis in non-small cell lung cancer patients receiving cisplatinbased chemotherapy. Value Health, 13, 41.
- Cox F and Hirsch J (1993). Ondansetron: a cost-effective advance in anti-emetic therapy. Oncol, 50, 186-90. https://doi.org/10.1159/000227175
- Cunningham D, Gore M, Davidson N, et al (1993). The real costs of emesis - an economic analysis of ondansetron versus metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur J Cancer, 29, 303-6.
- Erntoft S (2011). Pharmaceutical priority setting and the use of health economic evaluations: a systematic literature review. Value Health, 14, 587-99. https://doi.org/10.1016/j.jval.2010.10.036
- Ettinger DS, Armstrong DK, Barbour S, et al (2012). Antiemesis. JNCCN, 10, 456-85.
- Hassali MA, Thambyappa J, Nambiar S, et al (2013). TRIPS, Free Trade Agreements and the Pharmaceutical Industry in Malaysia. In "The New Political Economy of Pharmaceuticals: Production, Innnovation and TRIPS in the Global South", Eds Lofgren H and Williams OD. Palgrave Macmillan, Basingstoke pp 152-66.
- Humphreys S, Pellissier J, Jones A (2013). Cost-effectiveness of an aprepitant regimen for prevention of chemotherapyinduced nausea and vomiting in patients with breast cancer in the UK. Cancer Manag Res, 5, 215-24.
- Ismail F, Mohamed AK, Lim KH, et al (2011). Systemic therapy of cancer, 2nd edition. Ministry of Health, Kuala Lumpur, 75-8.
- Jordan K, Hinke A, Grothey A et al (2007). A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer, 15, 1023-33. https://doi.org/10.1007/s00520-006-0186-7
- Jordan K, Schmoll HJ, Aapro MS (2007). Comparative activity of antiemetic drugs. Oncol Hemato, 61, 162-75.
- Koeller JM, Aapro MS, Gralla RJ, et al (2002). Antiemetic guidelines: creating a more practical treatment approach. Supp Care Cancer, 10, 519-22. https://doi.org/10.1007/s00520-001-0335-y
- Kris MG, Hesketh PJ, Herrstedt J, et al (2005). Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Supp Care Cancer, 13, 85-96. https://doi.org/10.1007/s00520-004-0699-x
- Lordick F, Ehlken B, Ihbe-Heffinger A, et al (2007). Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer, 43, 299-307. https://doi.org/10.1016/j.ejca.2006.09.019
- Lopes G, Burke T, Pellissier J, et al (2012). Aprepitant for patients receiving highly-emetogenic chemotherapy: an economic analysis for Singapore. Value Health Regional Iss, 1, 66-74. https://doi.org/10.1016/j.vhri.2012.03.002
- Marshall DA and Hux M (2009). Design and analysis issues for economic analysis alongside clinical trials. Med Care, 47, 14-20. https://doi.org/10.1097/MLR.0b013e3181a31971
- Moore S, Tumeh J, Wojtanowski S, et al (2007). Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health, 10, 23-31. https://doi.org/10.1111/j.1524-4733.2006.00141.x
- Pharmacy Services Division Malaysia (2011). Drug Formulary. Ministry of Health, Kuala Lumpur pp 37.
- Rothermel C (2013). What is health economics and outcome research? A primer for medical writers. Am Med Writers Assoc J, 28, 98-104.
- Uyl-de Groot CA, Wait S, Buijt I (2000). Economics and healthrelated quality of life in antiemetic therapy: recommendations for trial design. Eur j Cancer, 36, 1522-35. https://doi.org/10.1016/S0959-8049(00)00132-5
- Yonemura M, Katsumata N, Hashimoto H, et al (2009). Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial. Jpn J Clin Oncol, 39, 443-8. https://doi.org/10.1093/jjco/hyp036
Cited by
- Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3951
- Aprepitant in the Prevention of Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10045
- Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6207